Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy
- 15 September 1990
- Vol. 66 (6) , 1276-1278
- https://doi.org/10.1002/1097-0142(19900915)66:6<1276::aid-cncr2820660629>3.0.co;2-a
Abstract
Dystrophic epidermolysis bullosa is associated with a high incidence of cutaneous squamous cell carcinoma. Despite aggressive surgical treatment, metastases occur frequently, and survival is generally poor. Chemotherapy for advanced disease has usually been avoided because of the potential for severe cutaneous toxicity. Two patients with autosomal recessive dystrophic epidermolysis bullosa and advanced squamous cell carcinoma are described. Both received cisplatin-based systemic chemotherapy without significant toxicity.This publication has 15 references indexed in Scilit:
- Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervixGynecologic Oncology, 1988
- Diabetic Patient With Crusted PlaquesArchives of Dermatology, 1987
- Epidermolysis BullosaInternational Journal of Dermatology, 1986
- Management of Squamous Cell Carcinoma in a Patient with Dominant-Type Epidermolysis Bullosa Dystrophica: A Surgical ChallengePlastic and Reconstructive Surgery, 1985
- CisplatinAnnals of Internal Medicine, 1984
- Recessive Dystrophic Epidermolysis bullosa and Multiple Squamous Cell CarcinomasDermatology, 1982
- Squamous cell carcinoma in dominant type epidermolysis bullosa dystrophicaCancer, 1981
- Phenytoin Therapy of Recessive Dystrophic Epidermolysis BullosaNew England Journal of Medicine, 1980
- Epidermolysis bullosa dystrophica and epithelioma of the skin.Review of published cases and report of an additional patientCancer, 1974
- Polydysplastic Epidermolysis Bullosa andArchives of Dermatology, 1970